ANANDA Scientific Announces a Clinical Trial Evaluating Nantheia™ ATL5, in the treatment of Co-Occurring Opioid Use Disorder and Chronic Pain

Contributed by: Business Wire

Logo

Images

(Photo: Business Wire)

Business Wire embedded0

Tags

Research

Neurology

Cannabis

Clinical Trials

Biotechnology

Health

Pharmaceutical

Science

Natural Resources

Nantheia ATL5

More Like This

(Photo: Business Wire)

ANANDA Scientific and the David Geffen School of Medicine, UCLA, Announce Commencement of a Clinical Trial Evaluating Nantheia™ ATL5 for Smoking Cessation

ANANDA PHARMA LTD ("Ananda" or the "Company") : MHRA and NHS Ethics Approval Received for ENDOCAN Phase 2 Clinical Trial for Endometriosis

PR Newswire associated0

AmacaThera doses First In Human Study to Evaluate, AMT-143, for Non-opioid Treatment of Post-operative Pain

Business Wire associated0

Ananda Scientific and Benta Sign Memorandum on Advancing Treatments for PTSD

PR Newswire associated0

AmacaThera Announces Phase 1 Results of First-in-Human Study with AMT-143, Exceeding Expectations and Paving the Way for a Novel Approach to Post-Operative Pain Relief

Tilray Medical Publishes Pioneering Research on the Pharmacokinetics of THC and CBD Formulations

CBD is approved for treatment-resistant epilepsy in children, and recent trials suggest that it may be useful for treating other disorders, such as schizophrenia and anxiety. Photo credit: Julia Zolotova

Quolet announces completion of Phase 1 healthy volunteer study evaluating the safety and bioavailability of Cannabidiol in a novel formulation intended for treatment of various neurological and psychiatric diseases

Avata Biosciences Emerges to Develop Solid Dose Cannabinoid Medicines for Epilepsy and Other Neurological Diseases